secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evofem Biosciences, Inc. (EVFM)
CIK:        0001618835
Form:       8-K
Filed at:   2024-01-11T23:59:59+00:00
Accession:  0001493152-24-002087
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.25
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evofem and Aditxt extend proxy filing deadline to Feb. 14, 2024 via first amendment to merger agreement
--------------------------------------------------------------------------------

- First Amendment to Merger Agreement moves Joint Proxy Statement filing date to February 14, 2024.
- No other terms of the December 11, 2023 merger agreement were changed.
- Merger Sub (Adicure) will merge into Evofem, with Evofem surviving as a wholly-owned subsidiary of Aditxt.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1618835/000149315224002087/0001493152-24-002087-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1618835/000149315224002087/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-002087

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer